MetaVia names Sarah Browne chief medical officer
- MetaVia named Sarah Browne as chief medical officer, effective Oct. 12, 2026.
- She was a clinical development consultant at Soufflé Therapeutics, advising on development planning and regulatory strategy.
- Browne previously led clinical development at Altimmune, advancing pemvidutide through Phase 2 and setting Phase 3 strategy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY70110) on October 13, 2026, and is solely responsible for the information contained therein.